Auron Therapeutics focuses on developing innovative therapies that harness the power of RNA-based technologies to address unmet medical needs. Their proprietary platform is designed to create targeted RNA therapeutics that can modulate gene expression with high specificity and efficacy. This approach allows for the development of treatments that can potentially overcome the limitations of traditional small molecule drugs and monoclonal antibodies, offering new avenues for addressing complex diseases.

The company’s pipeline includes a range of product candidates that leverage their RNA technology to target various disease pathways. Auron Therapeutics emphasizes the importance of precision medicine in their development strategy, aiming to tailor therapies to individual patient profiles. By utilizing advanced delivery mechanisms and optimizing RNA constructs, they strive to enhance the therapeutic potential of their products while minimizing off-target effects, thereby improving patient outcomes in challenging therapeutic areas.

United States

Auron Therapeutics is a privately held patient-centered, platform-powered, product-driven oncology company. We are the leaders in identifying and targeting cell state to treat a range of solid tumors and hematological malignancies.

Auron Therapeutics

Company Details